His scientific interests lie mostly in Internal medicine, Leukemia, Myeloid leukemia, Oncology and Surgery. His Internal medicine study incorporates themes from Gastroenterology and Immunology. The concepts of his Leukemia study are interwoven with issues in Myeloid, Chemotherapy and Pharmacology.
His Myeloid leukemia study introduces a deeper knowledge of Cancer research. His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Hematopoietic stem cell transplantation, Adverse effect, Myelodysplastic syndromes and Hazard ratio. His work investigates the relationship between Surgery and topics such as Bone marrow that intersect with problems in Lymphoma, Complication and Lenalidomide.
The scientist’s investigation covers issues in Internal medicine, Myeloid leukemia, Oncology, Leukemia and Cancer research. His studies in Internal medicine integrate themes in fields like Gastroenterology, Surgery and Immunology. His Oncology study combines topics in areas such as Clinical trial, Myelodysplastic syndromes and Transplantation.
His Leukemia study combines topics from a wide range of disciplines, such as Myeloid, Cancer, Haematopoiesis and Bone marrow. The various areas that he examines in his Cancer research study include Tyrosine kinase and Mutant. His Cytarabine research integrates issues from Daunorubicin and Induction chemotherapy.
Richard Stone mainly focuses on Internal medicine, Myeloid leukemia, Oncology, Cancer research and Leukemia. His study in Cytarabine, Transplantation, Chemotherapy, Clinical trial and Chemotherapy regimen falls under the purview of Internal medicine. His Myeloid leukemia research focuses on Adverse effect and how it connects with Febrile neutropenia.
His study in Oncology is interdisciplinary in nature, drawing from both European LeukemiaNet, Hematopoietic stem cell transplantation, NPM1 and Midostaurin. His research integrates issues of Haematopoiesis, Mutant and Kinase in his study of Cancer research. His Leukemia research is multidisciplinary, relying on both Myeloid and Cancer.
His primary scientific interests are in Internal medicine, Myeloid leukemia, Leukemia, Oncology and Myeloid. Cytarabine, Clinical trial, Transplantation, Adverse effect and Chemotherapy are subfields of Internal medicine in which his conducts study. His Myeloid leukemia study integrates concerns from other disciplines, such as Gastroenterology, Enasidenib and NPM1.
His Leukemia study is related to the wider topic of Immunology. His Oncology research includes themes of Ibrutinib, Surgery, Refractory and Rituximab. His Myeloid research is multidisciplinary, relying on both Survival rate, Bone marrow and MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll.
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover.
The New England Journal of Medicine (2003)
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
Lewis R. Silverman;Erin P. Demakos;Bercedis L. Peterson;Alice B. Kornblith.
Journal of Clinical Oncology (2002)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman.
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis.
The New England Journal of Medicine (2006)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman.
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg.
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Steven L. Soignet;Stanley R. Frankel;Dan Douer;Martin S. Tallman.
Journal of Clinical Oncology (2001)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard M. Stone;Sumithra J. Mandrekar;Ben L. Sanford;Kristina Laumann.
The New England Journal of Medicine (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: